Neurophet, a company specializing in artificial intelligence (AI) for diagnosing and treating brain diseases, said on the 10th that it signed a supply contract with the University of Washington in the United States for its brain imaging analysis solutions "Neurophet AQUA" and "Neurophet SCALE PET."
The contract is the first achievement in the process of entering the U.S. market following the establishment of its U.S. subsidiary in Oct. last year and the hiring of Josh Cohen as head of Americas business in Dec. of the same year. Neurophet secured a research institution reference in the United States through this and laid the groundwork for expanding its local business.
Neurophet AQUA is brain neurodegeneration imaging analysis software that performs ultrafast quantitative analysis of brain magnetic resonance imaging (MRI) to quantify the degree of brain atrophy and white matter degeneration. It analyzes changes in brain structure that appear in neurodegenerative diseases such as Alzheimer's disease and vascular dementia and provides a customized report.
Neurophet SCALE PET is positron emission tomography (PET) image quantitative analysis software that automatically calculates standardized uptake value ratio (SUVR) values for various radiotracers (PET tracers), including biomarkers related to Alzheimer's disease such as amyloid beta and tau proteins, as well as FDG and dopamine.
As Neurophet's comprehensive brain imaging analysis solution that supports prescribing Alzheimer's disease treatments, "Neurophet AQUA AD Plus," obtained 510(k) premarket clearance from the U.S. Food and Drug Administration (FDA) on the last month, the company plans to accelerate its push into the Americas market.
Bin Jun-gil, Neurophet's co-CEO, said, "By supplying to a U.S. research institution, we secured an initial reference for expanding our local business," and added, "Based on this, we will gradually expand our distribution channels in the United States."